Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | MME | P08473 | 2/20 | 0.42 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21431178 | 0.86 | CTSS (0.39) | LTA4HMME | |
| SCHEMBL27824390 | 0.83 | LTA4H (0.60) | LTA4HMMEOPRD1 | |
| SCHEMBL22909807 | 0.82 | ADAM17 (0.40) | MMP2 | |
| SCHEMBL22909614 | 0.81 | ADAM17 (0.41) | MMP2 | |
| SCHEMBL31634294 | 0.81 | LTA4H (0.62) | LTA4HMMEOPRD1 | |
| SCHEMBL27843494 | 0.81 | CAPN1 (0.48) | LTA4HCAPN1BIRC2 | |
| SCHEMBL31634273 | 0.80 | CTSK (0.49) | — | |
| SCHEMBL31634277 | 0.80 | CTSK (0.49) | — | |
| SCHEMBL31634276 | 0.80 | CTSK (0.49) | — | |
| SCHEMBL31634260 | 0.80 | CTSK (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11339193-B2 | CDP protein secretion inhibitors | KEZAR LIFE SCIENCES (US) | 2022-05-24 | — | — | US | disclosed |
| US-20210017233-A1 | CDP PROTEIN SECRETION INHIBITORS | ENODIA THERAPEUTICS SAS (FR) | 2021-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11339193-B2 | CDP protein secretion inhibitors | SEC61G, SEC61A1, SEC61B | LTA4H 3218/4885MME 1992/4885CAPN1 1556/4885 |
| US-20210017233-A1 | CDP PROTEIN SECRETION INHIBITORS | SEC61G, SEC61A1, SEC61B | LTA4H 3218/4885MME 1992/4885CAPN1 1556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.